These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 9202030

  • 1. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization.
    Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, Poruchynsky MS.
    J Biol Chem; 1997 Jul 04; 272(27):17118-25. PubMed ID: 9202030
    [Abstract] [Full Text] [Related]

  • 2. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
    Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, Poy G, Sackett D, Nicolaou KC, Fojo T.
    Proc Natl Acad Sci U S A; 2000 Mar 14; 97(6):2904-9. PubMed ID: 10688884
    [Abstract] [Full Text] [Related]

  • 3. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).
    Kowalski RJ, Giannakakou P, Hamel E.
    J Biol Chem; 1997 Jan 24; 272(4):2534-41. PubMed ID: 8999970
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
    Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, Nettles JH, Snyder JP, Greenberger LM.
    Mol Cancer Ther; 2006 Feb 24; 5(2):270-8. PubMed ID: 16505100
    [Abstract] [Full Text] [Related]

  • 5. Resistance to microtubule-stabilizing drugs involves two events: beta-tubulin mutation in one allele followed by loss of the second allele.
    Wang Y, O'Brate A, Zhou W, Giannakakou P.
    Cell Cycle; 2005 Dec 24; 4(12):1847-53. PubMed ID: 16294009
    [Abstract] [Full Text] [Related]

  • 6. The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site.
    Hamel E, Sackett DL, Vourloumis D, Nicolaou KC.
    Biochemistry; 1999 Apr 27; 38(17):5490-8. PubMed ID: 10220336
    [Abstract] [Full Text] [Related]

  • 7. Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents.
    Sackett DL, Giannakakou P, Poruchynsky M, Fojo A.
    Cancer Chemother Pharmacol; 1997 Apr 27; 40(3):228-32. PubMed ID: 9219506
    [Abstract] [Full Text] [Related]

  • 8. Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.
    Giannakakou P, Poy G, Zhan Z, Knutsen T, Blagosklonny MV, Fojo T.
    Oncogene; 2000 Jun 22; 19(27):3078-85. PubMed ID: 10871860
    [Abstract] [Full Text] [Related]

  • 9. Resistance mechanisms in human sarcoma mutants derived by single-step exposure to paclitaxel (Taxol).
    Dumontet C, Duran GE, Steger KA, Beketic-Oreskovic L, Sikic BI.
    Cancer Res; 1996 Mar 01; 56(5):1091-7. PubMed ID: 8640766
    [Abstract] [Full Text] [Related]

  • 10. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.
    Clin Cancer Res; 2001 May 01; 7(5):1429-37. PubMed ID: 11350914
    [Abstract] [Full Text] [Related]

  • 11. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI, Valoti G, Giannakakou P, Zhan Z, Kim JH, Lucchini V, Landoni F, Mayo JG, Giavazzi R, Fojo T.
    Clin Cancer Res; 2001 Sep 01; 7(9):2912-22. PubMed ID: 11555610
    [Abstract] [Full Text] [Related]

  • 12. Conservation of the class I beta-tubulin gene in human populations and lack of mutations in lung cancers and paclitaxel-resistant ovarian cancers.
    Sale S, Sung R, Shen P, Yu K, Wang Y, Duran GE, Kim JH, Fojo T, Oefner PJ, Sikic BI.
    Mol Cancer Ther; 2002 Jan 01; 1(3):215-25. PubMed ID: 12467216
    [Abstract] [Full Text] [Related]

  • 13. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Shimada M, Iba T, Naniwa J, Uegaki K, Terakawa N.
    Cancer Chemother Pharmacol; 2004 Mar 01; 53(3):247-52. PubMed ID: 14610615
    [Abstract] [Full Text] [Related]

  • 14. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism.
    Poruchynsky MS, Giannakakou P, Ward Y, Bulinski JC, Telford WG, Robey RW, Fojo T.
    Biochem Pharmacol; 2001 Dec 01; 62(11):1469-80. PubMed ID: 11728383
    [Abstract] [Full Text] [Related]

  • 15. Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Duran GE, Wang YC, Moisan F, Francisco EB, Sikic BI.
    Br J Cancer; 2017 May 09; 116(10):1318-1328. PubMed ID: 28399108
    [Abstract] [Full Text] [Related]

  • 16. βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.
    Kanakkanthara A, Northcote PT, Miller JH.
    Mol Cancer Ther; 2012 Feb 09; 11(2):393-404. PubMed ID: 22180309
    [Abstract] [Full Text] [Related]

  • 17. Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.
    Violini S, D'Ascenzo S, Bagnoli M, Millimaggi D, Miotti S, Canevari S, Pavan A, Dolo V.
    J Exp Clin Cancer Res; 2004 Mar 09; 23(1):83-91. PubMed ID: 15149155
    [Abstract] [Full Text] [Related]

  • 18. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
    Roque DM, Bellone S, Buza N, Romani C, Cocco E, Bignotti E, Ravaggi A, Rutherford TJ, Schwartz PE, Pecorelli S, Santin AD.
    Am J Obstet Gynecol; 2013 Jul 09; 209(1):62.e1-9. PubMed ID: 23583215
    [Abstract] [Full Text] [Related]

  • 19. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability.
    Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, Sackett DL, Fojo T.
    Biochemistry; 2004 Nov 09; 43(44):13944-54. PubMed ID: 15518543
    [Abstract] [Full Text] [Related]

  • 20. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells.
    Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E.
    Mol Pharmacol; 1997 Oct 09; 52(4):613-22. PubMed ID: 9380024
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.